Adjuvant therapy for renal cell carcinoma, finally a new standard?
Localized renal cell carcinoma (RCC) has the potential to be cured with surgery alone; however, some patients have a high risk of relapse and may benefit from additional treatment. Several efforts have been made to identify effective strategies, with mostly negative results. However, recent results...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.926661/full |
| _version_ | 1798000154501971968 |
|---|---|
| author | Alex Renner Carlos Rojas Annerleim Walton-Diaz Mauricio Burotto |
| author_facet | Alex Renner Carlos Rojas Annerleim Walton-Diaz Mauricio Burotto |
| author_sort | Alex Renner |
| collection | DOAJ |
| description | Localized renal cell carcinoma (RCC) has the potential to be cured with surgery alone; however, some patients have a high risk of relapse and may benefit from additional treatment. Several efforts have been made to identify effective strategies, with mostly negative results. However, recent results with immune checkpoint inhibitors may change the current standard, and several ongoing trials are exploring new alternatives. In this perspective, we aim to provide an overview of previous adjuvant therapy efforts, current data supporting the use of checkpoint blockade, and a future outlook for adjuvant therapy in renal cell carcinoma. |
| first_indexed | 2024-04-11T11:15:38Z |
| format | Article |
| id | doaj.art-eaf0d2a7df94459993cc3598db8f7cf3 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-11T11:15:38Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-eaf0d2a7df94459993cc3598db8f7cf32022-12-22T04:27:14ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-09-011210.3389/fonc.2022.926661926661Adjuvant therapy for renal cell carcinoma, finally a new standard?Alex Renner0Carlos Rojas1Annerleim Walton-Diaz2Mauricio Burotto3Medical Oncology Department, Bradford Hill Clinical Research Center, Santiago, ChileMedical Oncology Department, Bradford Hill Clinical Research Center, Santiago, ChileDepartment of Urology, Chilean National Cancer Institute, Urofusion Spa, and Department of Urology, Universidad de Chile, Santiago, ChileMedical Oncology Department, Bradford Hill Clinical Research Center, Santiago, ChileLocalized renal cell carcinoma (RCC) has the potential to be cured with surgery alone; however, some patients have a high risk of relapse and may benefit from additional treatment. Several efforts have been made to identify effective strategies, with mostly negative results. However, recent results with immune checkpoint inhibitors may change the current standard, and several ongoing trials are exploring new alternatives. In this perspective, we aim to provide an overview of previous adjuvant therapy efforts, current data supporting the use of checkpoint blockade, and a future outlook for adjuvant therapy in renal cell carcinoma.https://www.frontiersin.org/articles/10.3389/fonc.2022.926661/fullimmunotherapyrenal cell carcinomaadjuvantpembrolizumabtyrosine kinase inhibitions (TKIs) therapy |
| spellingShingle | Alex Renner Carlos Rojas Annerleim Walton-Diaz Mauricio Burotto Adjuvant therapy for renal cell carcinoma, finally a new standard? Frontiers in Oncology immunotherapy renal cell carcinoma adjuvant pembrolizumab tyrosine kinase inhibitions (TKIs) therapy |
| title | Adjuvant therapy for renal cell carcinoma, finally a new standard? |
| title_full | Adjuvant therapy for renal cell carcinoma, finally a new standard? |
| title_fullStr | Adjuvant therapy for renal cell carcinoma, finally a new standard? |
| title_full_unstemmed | Adjuvant therapy for renal cell carcinoma, finally a new standard? |
| title_short | Adjuvant therapy for renal cell carcinoma, finally a new standard? |
| title_sort | adjuvant therapy for renal cell carcinoma finally a new standard |
| topic | immunotherapy renal cell carcinoma adjuvant pembrolizumab tyrosine kinase inhibitions (TKIs) therapy |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.926661/full |
| work_keys_str_mv | AT alexrenner adjuvanttherapyforrenalcellcarcinomafinallyanewstandard AT carlosrojas adjuvanttherapyforrenalcellcarcinomafinallyanewstandard AT annerleimwaltondiaz adjuvanttherapyforrenalcellcarcinomafinallyanewstandard AT mauricioburotto adjuvanttherapyforrenalcellcarcinomafinallyanewstandard |